Skip to main content
SpringerLink
Log in

Schizophrenia and Gender

  • Chapter
  • First Online:
Psychopathology in Women

  • 1027 Accesses

Abstract

The existence of significant differences in schizophrenia is one of the issues discussed extensively. There are differences in the prognosis, marked by the age of onset, treatment adherence, or drug use. Another aspect is the clinical pattern (particularly cognitive symptoms), the response to treatment, and side effects. These differences can be explained on the basis of biological and psychosocial hypotheses. Schizophrenia is a very heterogeneous disorder, if we consider its basic clinical characteristics. That heterogeneity is showed by the vast variability in the onset and clinical presentation, the course of the illness, and response to both pharmacological and psychosocial treatment. That heterogeneity may be due to gender-related features, or at least gender variables may help to understand those differences. That’s why gender differences in schizophrenia have been widely studied in last decades. Unfortunately, research has not been conclusive for many of those differences.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Riecher-Rössler A, Butler S, Kulkarni J. Sex and gender differences in schizophrenic psychoses—a critical review. Arch Womens Ment Health. 2018;21:627–48. https://doi.org/10.1007/s00737-018-0847-9.

    Article  PubMed  Google Scholar 

  2. Ochoa S, Usall J, Cobo J, Labad X, Kulkarni J. Gender differences in schizophrenia and first-episode psychosis: a comprehensive literature review. Schizophr Res Treatment. 2012;2012:916198. https://doi.org/10.1155/2012/916198. Epub 8 Apr 2012.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Aleman A, Kahn RS, Selten JP. Sex differences in the risk of schizophrenia: evidence from meta-analysis. Arch Gen Psychiatry. 2003;60(6):565–71.

    Article  PubMed  Google Scholar 

  4. Zhang XY, Chen da C, Xiu MH, Yang FD, Haile CN, Kosten TA, Kosten TR. Gender differences in never-medicated first-episode schizophrenia and medicated chronic schizophrenia patients. J Clin Psychiatry. 2012;73(7):1025–33. https://doi.org/10.4088/JCP.11m07422.

    Article  PubMed  Google Scholar 

  5. McEvoy JP, Meyer JM, Goff DC, Nasrallah HA, Davis SM, Sullivan L, Meltzer HY, Hsiao J, Scott Stroup T, Lieberman JA. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANESIII. Schizophr Res. 2005;80(1):19–32. Epub 30 Aug 2005.

    Article  PubMed  Google Scholar 

  6. Chan RC, Chen EY, Cheung EF, Chen RY, Cheung HK. The components of executive functioning in a cohort of patients with chronic schizophrenia: a multiple single-case study design. Schizophr Res. 2006;81(2–3):173–89. Epub 26 Sept 2005.

    Article  PubMed  Google Scholar 

  7. Usall J, Busquets E, Araya S, Ochoa S, Gost A. Gender differences in schizophrenia. A literature review. Actas Esp Psiquiatr. 2000;28(3):178–85.

    CAS  PubMed  Google Scholar 

  8. Häfner H, Maurer K, Löffler W, Fätkenheuer B, an der Heiden W, Riecher-Rössler A, Behrens S, Gattaz WF. The epidemiology of early schizophrenia. Influence of age and gender on onset and early course. Br J Psychiatry Suppl. 1994;23:29–38.

    Article  Google Scholar 

  9. Esterberg M, Trotman HD, Holtzman C, Compton MT, Walker EF. The impact of a family history of psychosis on age-at-onset and positive and negative symptoms of schizophrenia: a meta-analysis. Schizophr Res. 2010;120(1–3):121–30. https://doi.org/10.1016/j.schres.2010.01.01.

    Article  PubMed  Google Scholar 

  10. Mendreck A, Mancini-Marïe A. Sex/gender differences in the brain and cognition in schizophrenia. Neurosci Biobehav Rev. 2016;67:57–78.

    Article  Google Scholar 

  11. Hafner H, Riecher A, Maurer K, Loffler W, Munk-Jorgensen P, Stromgren E. How does gender influence age at first hospitalization for schizophrenia? A transnational case register study. Psychol Med. 1989;19(4):903–18.

    Article  CAS  PubMed  Google Scholar 

  12. Bergen SE, O’Dushlaine CT, Lee PH, et al. Genetic modifiers and subtypes in schizophrenia: investigations of age at onset, severity, sex and family history. Schizophr Res. 2014;154(1–3):48–53.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Albus M, Scherer J, Hueber S, Lechleuthner T, Kraus G, Zausinger S, Burkes S. The impact of familial loading on gender differences in age at onset of schizophrenia. Acta Psychiatr Scand. 1994;89(2):132–4.

    Article  CAS  PubMed  Google Scholar 

  14. Van der Werf M, Hanssen M, Kohler S, Verkaaik M, Verhey FR, van Winkel R, van Os J, Allardyce J. Systematic review and collaborative recalculation of 133,693 incident cases of schizophrenia. Psychol Med. 2014;44(1):9–16.

    Article  PubMed  Google Scholar 

  15. Kirov G, Jones PB, Harvey I, Lewis SW, Toone BK, Rifkin L, Sham P, Murray RM. Do obstetric complications cause the earlier age at onset in male than female schizophrenics? Schizophr Res. 1996;20(1–2):117–24.

    Article  CAS  PubMed  Google Scholar 

  16. Verdoux H, Bourgeois M. A comparative study of obstetric history in schizophrenics, bipolar patients and normal subjects. Schizophr Res. 1993;9(1):67–9.

    Article  CAS  PubMed  Google Scholar 

  17. Forsyth JK, Ellman LM, Tanskanen A, Mustonen U, Huttunen MO, Suvisaari J, Cannon TD. Genetic risk for schizophrenia, obstetric complications, and adolescent school outcome: evidence for gene-environment interaction. Schizophr Bull. 2013;(5):1067–76. https://doi.org/10.1093/schbul/sbs098. Epub 1 Sept 2012.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Preti A, Cardascia L, Zen T, Marchetti M, Favaretto G, Miotto P. Risk for obstetric complications and schizophrenia. Psychiatry Res. 2000;96(2):127–39.

    Article  CAS  PubMed  Google Scholar 

  19. Goldstein JM, Faraone SV, Chen WJ, Tolomiczencko GS, Tsuang MT. Sex differences in the familial transmission of schizophrenia. Br J Psychiatry. 1990;156:819–26.

    Article  CAS  PubMed  Google Scholar 

  20. Pulver AE, Liang KY. Estimating effects of proband characteristics on familial risk. The association between age at onset and familial risk in the Maryland schizophrenia sample. Genet Epidemiol. 1991;8(5):339–50.

    Article  CAS  PubMed  Google Scholar 

  21. Goldstein JM, Cherkerzian S, Seidman LJ, Petryshen TL, Fitzmaurice G, Tsuang MT, Buka SL. Sex-specific rates of transmission of psychosis in the New England high-risk family study. Schizophr Res. 2011;128(1–3):150–5. https://doi.org/10.1016/j.schres.2011.01.019.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Goldstein JM, Cherkerzian S, Tsuang MT, Petryshen TL. Sex differences in the genetic risk for schizophrenia: history of the evidence for sex-specific and sex-dependent effects. Am J Med Genet B Neuropsychiatr Genet. 2013;162(7):698–710. https://doi.org/10.1002/ajmg.b.32159.

    Article  CAS  Google Scholar 

  23. Maier W, Lichtermann D, Minges J, Heun R, Halmayer J. The impact of gender and age at onset on the familial aggregation of schizophrenia. Eur Arch Psychiatry Clin Neurosci. 1993;242(5):279–85.

    Article  CAS  PubMed  Google Scholar 

  24. Crocker CE, Tibbo PG. The interaction of gender and cannabis in early phase psychosis. Schizophr Res. 2018;194:18–25.

    Article  PubMed  Google Scholar 

  25. González-Pinto A, Vega P, Ibáñez B, Mosquera F, Barbeito S, Gutiérrez M, Vieta E. Impact of cannabis and other drugs on age at onset of psychosis. J Clin Psychiatry. 2008;69(8):1210–6.

    Article  PubMed  Google Scholar 

  26. Foti DJ, Kotov R, Guey LT, Bromet EJ. Cannabis use and the course of schizophrenia: 10-year follow-up after first hospitalization. Am J Psychiatr. 2010;167(8):987–93.

    Article  PubMed  Google Scholar 

  27. Barnes TRE, Mutsatsa SH, Hutton SB, Watt HC, Joyce EM. Comorbid substance use and age at onset of schizophrenia. Br J Psychiatry. 2006;188:237–42.

    Article  PubMed  Google Scholar 

  28. Rodríguez-Jiménez R, Aragüés M, Jiménez-Arriero MA, et al. Dual diagnosis in psychiatric inpatients: prevalence and general characteristics. Invest Clin. 2008;49(2):195–205.

    PubMed  Google Scholar 

  29. Galderisi S, Bucci P, Üçok A, Peuskens J. No gender differences in social outcome in patients suffering from schizophrenia. J Eur Psychiatry. 2012;27(6):406–8.

    Article  CAS  Google Scholar 

  30. Arendt M, Rosenberg R, Foldager L, Perto G, Munk-Jørgensen P. Cannabis-induced psychosis and subsequent schizophrenia-spectrum disorders: follow-up study of 535 incident cases. Br J Psychiatry. 2005;187(6):510–5.

    Article  PubMed  Google Scholar 

  31. Thorup A, Albert N, Bertelsen M. Gender differences in first-episode psychosis at 5-year follow-up—two different courses of disease? Results from the OPUS study at 5-year follow-up. Eur Psychiatry. 2014;29(1):1–8.

    Article  Google Scholar 

  32. González-Pinto A, Alberich S, Ruiz de Azúa S, Martínez-Cengotitabengoa M, Fernández M, Gutiérrez M. Psychosis and smoking cessation: difficulties in quitting associated with sex and substance abuse. Psychiatry Res. 2012;195(1–2):45–50.

    Article  PubMed  Google Scholar 

  33. Lange EH, Nesvåg R, Ringen PA, Hartberg CB, Haukvik UK, Andreassen OA, Melle I, Agartz I. One year follow-up of alcohol and illicit substance use in first-episode psychosis: does gender matter? Compr Psychiatry. 2014;55(2):274–82. https://doi.org/10.1016/j.comppsych.2013.08.018.

    Article  PubMed  Google Scholar 

  34. Salokangas RK. Prognostic implications of the sex of schizophrenic patients. Br J Psychiatry. 1983;142(2):145–51.

    Article  CAS  PubMed  Google Scholar 

  35. Shtasel DL, Gur RE, Gallacher F, Heimberg C, Gur RC. Gender differences in the clinical expression of schizophrenia. Schizophr Res. 1992;7(3):225–31.

    Article  CAS  PubMed  Google Scholar 

  36. Tang YL, Gillespie CF, Epstein MP, Mao PX, Jiang F, Chen Q, Cai ZJ. Gender differences in 542 Chinese inpatients with schizophrenia. Schizophr Res. 2007;97(1–3):88–96. Epub 12 Jul 2007.

    Article  PubMed  Google Scholar 

  37. Allen DN, Strauss GP, Barchard KA, Vertinski M, Carpenter WT, Buchanan RW. Differences in developmental changes in academic and social premorbid adjustment between males and females with schizophrenia. Schizophr Res. 2013;146(1–3):132–7. https://doi.org/10.1016/j.schres.2013.01.032. Epub 13 Mar 2013.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Häfner H. Gender differences in schizophrenia. Psychoneuroendocrinology. 2003;28(Suppl 2):17–54.

    Article  PubMed  Google Scholar 

  39. Ittig S, Studerus E, Papmeyer M, Uttinger M, Koranyi S, Ramyead A, Riecher-Rössler A. Sex differences in cognitive functioning in at-risk mental state for psychosis, first episode psychosis and healthy control subjects. Eur Psychiatry. 2015;30:242–50. https://doi.org/10.1016/j.eurpsy.2014.11.006.

    Article  CAS  PubMed  Google Scholar 

  40. Krysta K, Murawiec S, Klasik A, Wiglusz MS, Krupka-Matuszczyk I. Sex-specific differences in cognitive functioning among schizophrenic patients. Psychiatr Danub. 2013;25:244–6.

    Google Scholar 

  41. Halari R, Mehrotra R, Sharma T, Ng V, Kumari V. Cognitive impairment but preservation of sexual dimorphism in cognitive abilities in chronic schizophrenia. Psychiatry Res. 2006;141(2):129–39.

    Article  PubMed  Google Scholar 

  42. Abu-Akel A, Bo S. Superior mentalizing abilities of female patients with schizophrenia. Psychiatry Res. 2013;201(3):794–9.

    Article  Google Scholar 

  43. Moriarty PJ, Lieber D, Bennett A, White L, Parrella M, Harvey PD, Davis KL. Gender differences in poor outcome patients with lifelong schizophrenia. Schizophr Bull. 2001;27(1):103–13.

    Article  CAS  PubMed  Google Scholar 

  44. Riecher-Rössler A, Häfner H, Stumbaum M, Maurer K, Schmidt R. Can estradiol modulate schizophrenic symptomatology? Schizophr Bull. 1994;20(1):203–14.

    Article  PubMed  Google Scholar 

  45. Lindamer LA, Buse DC, Lohr JB, Jeste DV. Hormone replacement therapy in postmenopausal women with schizophrenia: positive effect on negative symptoms? Biol Psychiatry. 2001;49(1):47–51.

    Article  CAS  PubMed  Google Scholar 

  46. Kulkarni J, Riedel A, de Castella AR, Fitzgerald PB, Rolfe TJ, Taffe J, Burger H. Estrogen a potential treatment for schizophrenia. Schizophr Res. 2001;41(1):137–44.

    Article  Google Scholar 

  47. Rao ML, Kölsch H. Effects of estrogen on brain development and neuroprotection—implications for negative symptoms in schizophrenia. Psychoneuroendocrinology. 2003;28(Suppl 2):83–96.

    Article  CAS  PubMed  Google Scholar 

  48. Keenan PA, Ezzat WH, Ginsburg K, Moore GJ. Prefrontal cortex as the site of estrogen’s effect on cognition. Psychoneuroendocrinology. 2001;26(6):577–90.

    Article  CAS  PubMed  Google Scholar 

  49. Myin-Germeys I, Krabbendam L, Delespaul PA, van Os J. Sex differences in emotional reactivity to daily life stress in psychosis. J Clin Psychiatry. 2004;65(6):805–9.

    Article  PubMed  Google Scholar 

  50. Cotton SM, Lambert M, Schimmelmann BG, Foley DL, Morley KI, McGorry PD, Conus P. Gender differences in premorbid, entry, treatment, and outcome characteristics in a treated epidemiological sample of 661 patients with first episode psychosis. Schizophr Res. 2009;114(1–3):17–24. https://doi.org/10.1016/j.schres.2009.07.002.

    Article  CAS  PubMed  Google Scholar 

  51. Kao YC, Liu YP. Effects of age of onset on clinical characteristics in schizophrenia. BMC Psychiatry. 2010;18:10–63. https://doi.org/10.1186/1471-244X-10-63.

    Article  Google Scholar 

  52. Angermeyer MC, Kühn L, Goldstein JM. Gender and the course of schizophrenia: differences in treated outcomes. Schizophr Bull. 1990;16(2):293–307.

    Article  CAS  PubMed  Google Scholar 

  53. Uggerby P, Nielsen RE, Correll CU, Nielsen J. Characteristics and predictors of long-term institutionalization in patients with schizophrenia. Schizophr Res. 2011;131(1–3):120–6. https://doi.org/10.1016/j.schres.2011.03.001. Epub 1 Apr 2011.

    Article  PubMed  Google Scholar 

  54. Opjordsmoen S. Long-term clinical outcome of schizophrenia with special reference to gender differences. Acta Psychiatr Scand. 1991;83(4):307–13.

    Article  CAS  PubMed  Google Scholar 

  55. Ram R, Bromet EJ, Eaton WW, Pato C, Schwartz JE. The natural course of schizophrenia: a review of first-admission studies. Schizophr Bull. 1992;18(2):185–207.

    Article  CAS  PubMed  Google Scholar 

  56. McEwen BS, Milner TA. Understanding the broad influence of sex hormones and sex differences in the brain. J Neurosci Res. 2017;95(1–2):24–39. https://doi.org/10.1002/jnr.23809.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Ingalhalikar M, Smith A, Parker D, Satterthwaite TD, Elliott MA, Ruparel K. Sex differences in the structural connectome of the human brain. Proc Natl Acad Sci U S A. 2014;111(2):823–8. https://doi.org/10.1073/pnas.1316909110.

    Article  CAS  PubMed  Google Scholar 

  58. Walder DJ, Yaffe B, Ehrlich Y. Chapter 5—Sexual dimorphisms in psychosis risk: a neurodevelopmental perspective. In: Shansky RM, editor. Sex differences in the central nervous system. San Diego, CA: Academic Press; 2016. p. 107–27. https://doi.org/10.1016/B978-0-12-802114-9.00005-6.

    Chapter  Google Scholar 

  59. Nopoulos P, Laum M, Andreasen NC. Sex differences in brain morphology in schizophrenia. Am J Psychiatry. 1997;154:1648–54.

    Article  CAS  PubMed  Google Scholar 

  60. Gur RE, Mozley PD, Shtasel DL, Cannon TD, Gallacher F, Turetsky B, Grossman R, Gur RC. Clinical subtypes of schizophrenia: differences in brain and CSF volume. Am J Psychiatry. 1994;151(3):343–50.

    Article  CAS  PubMed  Google Scholar 

  61. Lewine RRJ, Gulley LR, Risch SC, Jewart R, Houpt JL. Sexual dimorphism, brain morphology and schizophrenia. Schizophr Bull. 1990;16:195–204.

    Article  CAS  PubMed  Google Scholar 

  62. Raine A, Harrison GN, Reynolds GP, Sheard C, Cooper JE, Medley I. Structural and functional characteristics of the corpus callosum in schizophrenics, psychiatric controls and normal controls. A magnetic resonance imaging and neuropsychological evaluation. Arch Gen Psychiatry. 1990;47(11):1060–4.

    Article  CAS  PubMed  Google Scholar 

  63. Ward KE, Friedman L, Wise A, Schulz SC. Meta-analysis of brain and cranial size in schizophrenia. Schizophr Res. 1996;22:197–213.

    Article  CAS  PubMed  Google Scholar 

  64. Haijma SV, Van Haren N, Cahn W. Brain volumes in schizophrenia: a meta-analysis in over 18.000 subjects. Schizophr Bull. 2013;39(5):1129–38.

    Article  PubMed  Google Scholar 

  65. Gruner P, Christopher C, Robinson DG. Pituitary volumen in first episode schizophrenia. Psychiatry Res Neuroimaging. 2012;203:100–2.

    Article  Google Scholar 

  66. Romo-Nava F, Hoogenboom WS, Pelavin PE. Pituitary volume in schizophrenia spectrum disorders. Schizophr Res. 2013;146:301–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. Cowell PE, Kostianovsky DJ. Sex differences in neuroanatomical and clinical correlations in schizophrenia. Am J Psychiatry. 1996;153(6):799.

    Article  CAS  PubMed  Google Scholar 

  68. Malla AK, Tarhar J, Norman RMG, Assis L. Computed tomographic findings in schizphrenia: relation with symptom dimensions and sex differences. J Psychiatry Neurosci. 1999;24(2):131–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  69. Falkenburg J, Tracy DK. Sex and schizophrenia: a review of gender differences. Psychosis. 2014;6(1):61–9. https://doi.org/10.1080/17522439.2012.733405.

    Article  Google Scholar 

  70. McGregor C, et al. Estrogens and the cognitive symptoms of schizophrenia: possible neuroprotective mechanisms. Front Neuroendocrinol. 2017;47:19–33.

    Article  CAS  PubMed  Google Scholar 

  71. Hafner H. Gender differences in schizophrenia. Psychoneuroendocrinology. 2003;28(Suppl 2):17–54.

    Article  PubMed  Google Scholar 

  72. Angermeyer MC, Kuhn L. Gender differences in age at onset of schizophrenia. An overview. Eur Arch Psychiatry Neurol Sci. 1988;237:351–64.

    Article  CAS  PubMed  Google Scholar 

  73. Eranti SV, Maccabe JH, Bundy H, Murray RM. Gender difference in age at onset of schizophrenia: a meta-analysis. Psychol Med. 2013;43:155–67.

    Article  CAS  PubMed  Google Scholar 

  74. Thara R, Kamath S. Women and schizophrenia. Indian J Psychiatry. 2015;57(Suppl 2):246–51.

    Article  Google Scholar 

  75. Thara R. Twenty year course of schizophrenia: the Madras Longitudinal Study. Can J Psychiatr. 2004;49:564–9.

    Article  CAS  Google Scholar 

  76. Canuso CM, Pandina G. Gender and schizophrenia. Psychopharmacol Bull. 2007;40:178–90.

    PubMed  Google Scholar 

  77. Castle D, Sham P, Murray R. Differences in distribution of ages of onset in males and females with schizophrenia. Schizophr Res. 1998;33:179–83.

    Article  CAS  PubMed  Google Scholar 

  78. Loranger AW. Sex difference in age at onset of schizophrenia. Arch Gen Psychiatry. 1984;41:157–61.

    Article  CAS  PubMed  Google Scholar 

  79. Goldstein JM, Seidman LJ, Goodman JM, Koren D, Lee H, Weintraub S, Tsuang MT. Are there sex differences in neuropsychological functions among patients with schizophrenia? Am J Psychiatry. 1998;155:1358–64.

    Article  CAS  PubMed  Google Scholar 

  80. Torniainen M, Suvisaari J, Partonen T, Castaneda A, Kuha A, Perala J. Differences in cognition among persons with schizophrenia and healthy first-degree relatives. Psychiatry Res. 2011;188:7–12.

    Article  PubMed  Google Scholar 

  81. Han M, Huang X, Xiu M, Hui L, Liu H, Kosten T, Zhang X. Gender differences in cognitive function of patients with chronic schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2012;39:358–63.

    Article  PubMed  Google Scholar 

  82. Vaskinn A, Sundet K, Simonsen C, Hellvin T, Melle I, Andreassen OA. Sex differences in neuropsychological performance and social functioning in schizophrenia and bipolar disorder. Neuropsychology. 2011;25:499–510.

    Article  PubMed  Google Scholar 

  83. Seeman MV, Lang M. The role of estrogens in schizophrenia gender differences. Schizophr Bull. 1990;16(2):185–94.

    Article  CAS  PubMed  Google Scholar 

  84. Supprian T, Kalus P. Sexual dimorphism of the human brain—a review of the literature. Fortschr Neurol Psychiatr. 1996;64(10):382–9.

    Article  CAS  PubMed  Google Scholar 

  85. Saugstad LF. The maturational theory of brain development and cerebral excitability in the multifactorially inherited manic-depressive psychosis and schizophrenia. Int J Psychophysiol. 1994;18(3):189–203.

    Article  CAS  PubMed  Google Scholar 

  86. Downhill JE Jr, Buchsbaum MS, Wei T, Spiegel-Cohen J, Hazlett EA, Haznedar MM, Silverman J, Siever LJ. Shape and size of the corpus callosum in schizophrenia and schizotypal personality disorder. Schizophr Res. 2000;42(3):193–208.

    Article  PubMed  Google Scholar 

  87. Häfner H, an der Heiden W, Hambrecht M, Riecher-Rössler A, Maurer K, Löffler W, Fätkenheuer B. A chapter in systematic schizophrenia research the search for causal explanations for sex differences in age of onset. Nervenarzt. 1993;64(11):706–16.

    PubMed  Google Scholar 

  88. Leung A, Chue P. Sex differences in schizophrenia, a review of the literature. Acta Psychiatr Scand Suppl. 2000;401:3–38.

    Article  CAS  PubMed  Google Scholar 

  89. Haus-Seuffert P, Meisterernst M. Mechanisms of transcriptional activation of cAMP-responsive element-binding protein CREB. Mol Cell Biochem. 2000;212(1–2):5–9.

    Article  CAS  PubMed  Google Scholar 

  90. Kölsch H, Lütjohann D, Tulke A, Björkhem I, Rao ML. The neurotoxic effect of 24-hydroxycholesterol on SH-SY5Y human neuroblastoma cells. Brain Res. 1999;818(1):171–5.

    Article  PubMed  Google Scholar 

  91. Kölsch H, Ludwig M, Lütjohann D, Rao ML. Neurotoxicity of 24-hydroxycholesterol, an important cholesterol elimination product of the brain, may be prevented by vitamin E and estradiol-17beta. J Neural Transm. 2001;108(4):475–88.

    Article  PubMed  Google Scholar 

  92. Riecher-Rössler A, Butler S, Kulkarni J. Sex and gender differences in schizophrenic psychoses—a critical review. Arch Womens Ment Health. 2018;2018:1–22.

    Google Scholar 

  93. Hughes ZA, Liu F, Marquis K, Muniz L, Pangalos MN, Ring RH, Whiteside GJ, Brandon NJ. Estrogen receptor neurobiology and its potential for translation into broad spectrum therapeutics for CNS disorders. Curr Mol Pharmacol. 2009;2:215–36.

    Article  CAS  PubMed  Google Scholar 

  94. Taylor GT, Maloney S, Dearborn J, et al. Hormones in the mentally disturbed brain: steroids and peptides in the development and treatment of psychopathology. Cent Nerv Syst Agents Med Chem. 2009;9(4):331–60.

    Article  CAS  PubMed  Google Scholar 

  95. Kulkarni J, Hayes E, Gavrilidis E. Hormones and schizophrenia. Curr Opin Psychiatry. 2012;25:89–95.

    Article  PubMed  Google Scholar 

  96. Kulkarni J, Gavrilidis E, Worsley R, Hayes E. Role of estrogen treatment in the management of schizophrenia. CNS Drugs. 2012;26(7):549–57.

    Article  CAS  PubMed  Google Scholar 

  97. Kendell RE, Chalmers JC, Platz C. Epidemiology of puerperal psychoses. Br J Psychiatry. 1987;150:662–73.

    Article  CAS  PubMed  Google Scholar 

  98. Riecher-Rossler A, Seeman MV. Oestrogens and schizophrenia: introduction. Arch Womens Ment Health. 2002;5(3):91–2.

    Article  CAS  PubMed  Google Scholar 

  99. Seeman MV. Psychopathology in women and men: focus on female hormones. Am J Psychiatry. 1997;154(12):1641–7.

    Article  CAS  PubMed  Google Scholar 

  100. Wickens MM, Bangasser DA, Briand LA. Sex differences in Psychiatry Disease: A Focus on the Glutamate System. Front Mol Neurosci. 2018;11:197.

    Article  PubMed  PubMed Central  Google Scholar 

  101. Magri C, Gardella R, Valsecchi P, Barlati SD, Guizzetti L, Imperadori L, et al. Study on GRIA2, GRIA3 and GRIA4 genes highlights a positive association between schizophrenia and GRIA3 in female patients. Am J Med Genet B Neuropsychiatr Genet. 2008;147B:745–53. https://doi.org/10.1002/ajmg.b.30674.

    Article  CAS  PubMed  Google Scholar 

  102. Olney JW, Farber NB. Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry. 1995;52:998–1007. https://doi.org/10.1001/archpsyc.1995.03950240016004.

    Article  CAS  PubMed  Google Scholar 

  103. Goff DC, Coyle JT. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am J Psychiatry. 2001;158:1367–77. https://doi.org/10.1176/appi.ajp.158.9.1367.

    Article  CAS  PubMed  Google Scholar 

  104. Coyle JT, Tsai G, Goff DC. Ionotropic glutamate receptors as therapeutic targets in schizophrenia. Curr Drug Targets CNS Neurol Disord. 2002;1:183–9. https://doi.org/10.2174/1568007024606212.

    Article  CAS  PubMed  Google Scholar 

  105. Tsai G, Coyle JT. Glutamatergic mechanisms in schizophrenia. Annu Rev Pharmacol Toxicol. 2002;42:165–79. https://doi.org/10.1146/annurev.pharmtox.42.082701.160735.

    Article  CAS  PubMed  Google Scholar 

  106. Javitt DC. Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions. Int Rev Neurobiol. 2007;78:69–108. https://doi.org/10.1016/S0074-7742(06)78003-5.

    Article  CAS  PubMed  Google Scholar 

  107. Martins-de-Souza D, Maccarrone G, Wobrock T, Zerr I, Gormanns P, Reckow S, et al. Proteome analysis of the thalamus and cerebrospinal fluid reveals glycolysis dysfunction and potential biomarkers candidates for schizophrenia. J Psychiatr Res. 2010;44:1176–89. https://doi.org/10.1016/j.jpsychires.2010.04.014.

    Article  PubMed  Google Scholar 

  108. Nudmamud-Thanoi S, Reynolds GP. The NR1 subunit of the glutamate/NMDA receptor in the superior temporal cortex in schizophrenia and affective disorders. Neurosci Lett. 2004;372:173–7. https://doi.org/10.1016/j.neulet.2004.09.035.

    Article  CAS  PubMed  Google Scholar 

  109. Seeman MV. Gender differences in the prescribing of antipsychotic drugs. Am J Psychiatry. 2004;161:1324–33.

    Article  PubMed  Google Scholar 

  110. Yonkers KA, Kando JC, Cole JO, et al. Gender Differences in Pharmacokinetics and Pharmacodynamics of Psychotropic Medication. Am J Psychiatry. 1992;149:587–95.

    Article  CAS  PubMed  Google Scholar 

  111. Seeman MV. Interaction of sex, age, and neuroleptic dose. Compr Psychiatry. 1983;24(2):125–8.

    Article  CAS  PubMed  Google Scholar 

  112. Galderisi S, Bucci P, Üçok A, Peuskens J. No gender differences in social outcome in patients suffering from schizophrenia. Eur Psychiatry. 2012;27(6):406–8.

    Article  CAS  PubMed  Google Scholar 

  113. Kelly DL, Conley RR, Tamminga CA. Differential olanzapine plasma concentrations by sex in a fixed-dose study. Schizophr Res. 1999;40(2):222–39.

    Article  Google Scholar 

  114. Harris RZ, Benet LZ, Schwartz JB. Gender effects in pharmacokinetics and pharmacodynamics. Drugs. 1995;50:222–39.

    Article  CAS  PubMed  Google Scholar 

  115. Sica DA, Wood M, Hess M. Gender and its effect in cardiovascular pharmacotherapeutics: recent considerations. Congest Heart Fail. 2005;11(3):163–6.

    Article  CAS  PubMed  Google Scholar 

  116. Schwartz JB. The influence of sex on pharmacokinetics. Clin Pharmacokinet. 2003;42:107–21.

    Article  CAS  PubMed  Google Scholar 

  117. Seeman MV. Neuroleptic expressed prescription for men and women. Social Pharmacol. 1989;3:219–36.

    Google Scholar 

  118. Haring C, Meise U, Humpel C, et al. Dose-related plasma levels of clozapine: influence of smoking behavior, sex, and age. Psychopharmacology. 1989;99(1):38–40.

    Article  Google Scholar 

  119. Hughes JR. Possible effects of smoker-free inpatient units on psychiatric diagnosis and treatment. J Clin Psychiatry. 1993;54:109–14.

    CAS  PubMed  Google Scholar 

  120. Goff DC, Henderson DC, Amico E. Cigarette smoking in schizophrenia: relationship to psychopathology and medication side effects. Am J Psychiatry. 1992;149(9):1189–94.

    Article  CAS  PubMed  Google Scholar 

  121. Callaghan JT, Bergstrom RF, Ptak LR, et al. Olanzapine: pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet. 1999;37:177–93.

    Article  CAS  PubMed  Google Scholar 

  122. Carrillo JA, Herraiz AG, Ramos SI, et al. Role of the smoking-induced cytochrome P450 (CYP)1A2 and polymorphic CYP2D6 in steady-state concentration of olanzapine. J Clin Psychopharmacol. 2003;23(2):119–27.

    Article  CAS  PubMed  Google Scholar 

  123. Crawford MB, DeLisi LE. Issues related to sex differences in antipsychotic treatment. Curr Opin Psychiatry. 2016;29(3):211–7.

    Article  PubMed  Google Scholar 

  124. Haas GL, Glick ID, Clarkin JF, Spencer JH, Lewis AB. Gender and schizophrenia outcome: a clinical trial of an inpatient family intervention. Schizophr Bull. 1990;16(2):277–92.

    Article  CAS  PubMed  Google Scholar 

  125. Davis JA, Goldstein MJ, Nuechterlein KH. Gender differences in family attitudes about schizophrenia. Psychol Med. 1996;26(4):689–96.

    Article  CAS  PubMed  Google Scholar 

  126. Riecher-Rössler A, Häfner H. Gender aspects in schizophrenia: bridging the border between social and biological psychiatry. Acta Psychiatr Scand Suppl. 2000;102:58–62.

    Article  Google Scholar 

  127. Abel KM, Drake R, Goldstein JM. Sex differences in schizophrenia. Int Rev Psychiatry. 2010;22:417–28.

    Article  PubMed  Google Scholar 

  128. Ochoa S, Usall J, Cobo J, et al. Gender differences in schizophrenia and first-episode psychosis: a comprehensive literature review. Schizophr Res Treat. 2012;2012:916198.

    Google Scholar 

  129. Cotton SM, Lambert M, Schimmelmann BG, et al. Gender differences in premorbid, entry, treatment, and outcome characteristics in a treated epidemiological sample of 661 patients with first episode psychosis. Schizophr Res. 2009;114:17–24.

    Article  CAS  PubMed  Google Scholar 

  130. da Silva TL, Ravindrana AV. Contribution of sex hormones to gender differences in schizophrenia: a review. Asian J Psychiatr. 2015;18:2–14.

    Article  PubMed  Google Scholar 

  131. Szymanski S, Lieberman JA, Alvir JM, et al. Gender differences in onset of illness, treatment response, course, and biologic indexes in first-episode schizophrenic patients. Am J Psychiatry. 1995;152(5):698–703.

    Article  CAS  PubMed  Google Scholar 

  132. Seeman MV. Current outcome in schizophrenia: women vs men. Acta Psychiatr Scand. 1986;73(6):609–17.

    Article  CAS  PubMed  Google Scholar 

  133. Robinson DG, Woerner MG, Alvir JMJ, et al. Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry. 1999;156(4):544–9.

    CAS  PubMed  Google Scholar 

  134. Sellwood W, Tarrier N. Demographic factors associated with extreme non-compliance in schizophrenia. Soc Psychiatry Psychiatr Epidemiol. 1994;29(4):172–7.

    CAS  PubMed  Google Scholar 

  135. Nose M, Barbui C, Tansella M. How often do patients with psychosis fail to adhere to treatment programmes? A systematic review. Psychol Med. 2003;33(7):1149–60.

    Article  CAS  PubMed  Google Scholar 

  136. Law MR, Soumerai SB, Ross-Degnan D, et al. A longitudinal study of medication nonadherence and hospitalization risk in schizophrenia. J Clin Psychiatry. 2008;69:47–53.

    Article  PubMed  Google Scholar 

  137. Lo WH, Lo T. A ten-year follow-up study of Chinese schizophrenics in Hong Kong. Br J Psychiatry. 1977;131(1):2.

    Article  Google Scholar 

  138. Galdas PM, Cheater F, Marshall P. Men and health help-seeking behaviour: literature review. J Adv Nurs. 2005;49(6):616–23.

    Article  PubMed  Google Scholar 

  139. Kulkarni J, Gavrilidis E, Wang W, et al. Estradiol for treatment-resistant schizophrenia: a large-scale randomized-controlled trial in women of child-bearing age. Mol Psychiatry. 2015;20(6):695–702.

    Article  CAS  PubMed  Google Scholar 

  140. Begemann MJH, Dekker CF, van Lunenburg M, et al. Estrogen augmentation in schizophrenia: a quantitative review of current evidence. Schizophr Res. 2012;141(2–3):179–84.

    Article  PubMed  Google Scholar 

  141. Ghafari E, Fararouie M, Shirazi HG, et al. Combination of estrogen and antipsychotics in the treatment of women with chronic schizophrenia. Clin Schizophr Relat Psychoses. 2013;6(4):172–6.

    Article  PubMed  Google Scholar 

  142. Melkersson KI, Hulting AL, Rane AJ. Dose requirement and prolactin elevation of antipsychotics in male and female patients with schizophrenia or related psychoses. Br J Clin Pharmacol. 2001;51(4):317–24.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  143. Carliner H, Collins PY, Cabassa LJ, et al. Prevalence of cardiovascular risk factors among racial and ethnic minorities with schizophrenia spectrum and bipolar disorders: a critical literature review. Compr Psychiatry. 2014;55(2):233–47.

    Article  PubMed  Google Scholar 

  144. Bener A, Al-Hamaq AO, Dafeeah EE. A two fold risk of metabolic syndrome in a sample of patients with schizophrenia: do consanguinity and family history increase risk? Diabetes Metab Syndr. 2014;8(1):24–9.

    Article  PubMed  Google Scholar 

  145. Huang MC, Lu ML, Tsai CJ, et al. Prevalence of metabolic syndrome among patients with schizophrenia or schizoaffective disorder in Taiwan. Acta Psychiatr Scand. 2009;120:274–80.

    Article  PubMed  Google Scholar 

  146. Meyer JM, Nasrallah HA, McEvoy JP, et al. The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Trial: clinical comparison of subgroups with and without the metabolic syndrome. Schizophr Res. 2005;80(1):9–18.

    Article  PubMed  Google Scholar 

  147. Boke O, Aker S, Sarisoy G, Saricicek EB, Sahin AR. Prevalence of metabolic syndrome among inpatients with schizophrenia. Int J Psychiatry Med. 2008;38(1):103–12.

    Article  PubMed  Google Scholar 

  148. Bobes J, Arango C, Aranda P, Carmena R, Garcia-Garcia M, Rejas J, CLAMORS Study Collaborative Group. Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: results of the CLAMORS Study. Schizophr Res. 2007;90(1–3):162–73.

    Article  PubMed  Google Scholar 

  149. Xiang YT, Wang CY, Weng YZ, et al. Sex differences in patients with schizophrenia: a prospective, multi-center study. Psychiatry Res. 2010;177:294–8.

    Article  PubMed  Google Scholar 

  150. Limosin F, Gasquet I, Leguay D, et al. Body mass index and prevalence of obesity in a French cohort of patients with schizophrenia. Acta Psychiatr Scand. 2008;118(1):19–25.

    Article  CAS  PubMed  Google Scholar 

  151. Verma S, Liew A, Subramaniam M, et al. Effect of treatment on weight gain and metabolic abnormalities in patients with first-episode psychosis. Aust N Z J Psychiatry. 2009;43(9):812–7.

    Article  PubMed  Google Scholar 

  152. Seeman MV. Secondary effects of antipsychotics: women at greater risk than men. Schizophr Bull. 2009;35(5):937–48.

    Article  PubMed  Google Scholar 

  153. Vieweg WV, Wood MA, Fernandez A, et al. Proarrhythmic risk with antipsychotic and antidepressant drugs: implications in the elderly. Drugs Aging. 2009;26(12):997–1012.

    Article  CAS  PubMed  Google Scholar 

  154. Meltzer HY, Busch D. Serum prolactin response to chlorpromazine and psychopathology in schizophrenics: implications for the dopamine hypothesis. Psychiatry Res. 1983;9(4):285–99.

    Article  CAS  PubMed  Google Scholar 

  155. Nathan RS, Sachar EJ, Ostrow L, et al. A preliminary study of sex-related differences in prolactin responses to dopamine blockade and insulin hypoglycemia and in penfluridol plasma levels in schizophrenic patients. Psychopharmacology. 1983;80(1):46–9.

    Article  CAS  PubMed  Google Scholar 

  156. Koreen AR, Lieberman J, Alvir J, et al. Plasma homovanillic acid levels in first-episode schizophrenia. Psychopathology and treatment response. Arch Gen Psychiatry. 1994;51(2):132–8.

    Article  CAS  PubMed  Google Scholar 

  157. Sumiyoshi T, Hasegawa M, Jayathilake K, et al. Sex differences in plasma homovanillic acid levels in schizophrenia and normal controls: relation to neuroleptic resistance. Biol Psychiatry. 1997;41(5):560–6. 193(3):153–6.

    Article  CAS  PubMed  Google Scholar 

  158. Yasui N, Kondo T, Otani K, et al. Prolactin response to bromperidol treatment in schizophrenic patients. Pharmacol Toxicol. 1998;82:153–6.

    Article  CAS  PubMed  Google Scholar 

  159. O’Keane V. Review antipsychotic-induced hyperprolactinaemia, hypogonadism and osteoporosis in the treatment of schizophrenia. J Psychopharmacol. 2008;22(2 Suppl):70–5.

    Article  PubMed  Google Scholar 

  160. Dursun SM, Wildgust HJ, Strickland P, Goodwin GM, Citrome L, Lean M. The emerging physical health challenges of antipsychotic associated hyperprolactinaemia in patients with serious mental illness. J Psychopharmacol. 2008;22(2 Suppl):3–5.

    Article  PubMed  Google Scholar 

  161. Halbreich U, Kahn LS. Hormonal aspects of schizophrenias: an overview. Psychoneuroendocrinology. 2003;28:1–16.

    CAS  PubMed  Google Scholar 

  162. Stubbs B, De Hert M, Sepehry AA, et al. A meta-analysis of prevalence estimates and moderators of low bone mass in people with schizophrenia. Acta Psychiatr Scand. 2014;130(6):470–86.

    Article  CAS  PubMed  Google Scholar 

  163. Halbreich U, Rojansky N, Palter S, et al. Decreased bone mineral density in medicated psychiatric patients. Psychosom Med. 1995;57(5):485–91.

    Article  CAS  PubMed  Google Scholar 

  164. Hummer M, Malik P, Gasser RW, et al. Osteoporosis in patients with schizophrenia. Am J Psychiatry. 2005;162:162–7.

    Article  PubMed  Google Scholar 

  165. Alvir JM, Lieberman JA. A reevaluation of the clinical characteristics of clozapineinduced agranulocytosis in light of the United States experience. J Clin Psychopharmacol. 1994;14:87–9.

    CAS  PubMed  Google Scholar 

  166. Banov MD, Tohen M, Friedberg J. High risk of eosinophilia in women treated with clozapine. J Clin Psychiatry. 1993;54:466–9.

    CAS  PubMed  Google Scholar 

  167. Auquier P, Lançon C, Rouillon F, et al. Mortality in schizophrenia. Pharmacoepidemiol Drug Saf. 2006;15(12):873–9.

    Article  PubMed  Google Scholar 

  168. Targum SD, Caputo KP, Ball SK. Menstrual cycle phase and psychiatric admissions. J Affect Disord. 1991;22(1):49–53.

    Article  CAS  PubMed  Google Scholar 

  169. Lande RG, Karamchandani V. Chronic mental illness and the menstrual cycle. J Am Osteopath Assoc. 2002;102(12):655–9.

    PubMed  Google Scholar 

  170. Riecher-Rössler, A.W., Estrogens and schizophrenia, in Oestrogen effects in psychiatric disorders, N. Bergemann and A. Riecher-Rössler. 2005, Springer-Verlag Wien 31–52.

    Google Scholar 

  171. Thompson KN, Kulkarni J, Sergejew AA. Extrapyramidal symptoms and oestrogen. Acta Psychiatr Scand. 2000;101(2):130–4.

    Article  CAS  PubMed  Google Scholar 

  172. Goldstein JM, Cohen LS, Horton NJ, et al. Sex differences in clinical response to olanzapine compared with haloperidol. Psychiatry Res. 2002;110(1):27–37.

    Article  CAS  PubMed  Google Scholar 

  173. Just MJ. The influence of atypical antipsychotic drugs on sexual function. Neuropsychiatr Dis Treat. 2015;11:1655–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  174. Seeman MV. Antipsychotic-induced amenorrhea. J Ment Health. 2011;20:484–91.

    Article  PubMed  Google Scholar 

  175. Miller LJ. Sexuality, reproduction, and family planning in women with schizophrenia. Schizophr Bull. 1997;23(4):623–35.

    Article  CAS  PubMed  Google Scholar 

  176. Seeman MV. Menstrual exacerbation of schizophrenia symptoms. Acta Psychiatr Scand. 2012;125:363–71.

    Article  CAS  PubMed  Google Scholar 

  177. Galbally M, Snellen M, Power J. Antipsychotic drugs in pregnancy: a review of their maternal and fetal effects. Ther Adv Drug Saf. 2014;5(2):100–9.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  178. McCauley-Elsom K, Kulkarni J. Managing psychosis in pregnancy. Aust N Z J Psychiatry. 2007;41(3):289–92.

    Article  PubMed  Google Scholar 

  179. Sadowski A, Todorow M, Yazdani Brojeni P, et al. Pregnancy outcomes following maternal exposure to second-generation antipsychotics given with other psychotropic drugs: a cohort study. Br Med J Open. 2013;3(7):e003062.

    Google Scholar 

  180. Hasan A, Falkai P, Wobrock T, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia part 3: update 2015 management of special circumstances: depression, suicidality, substance use disorders and pregnancy and lactation. World J Biol Psychiatry. 2015;16:142–70.

    Article  PubMed  Google Scholar 

  181. Mehta TM, Van Lieshout RJ. A review of the safety of clozapine during pregnancy and lactation. Arch Womens Ment Health. 2016;20(1):1–9.

    Article  PubMed  Google Scholar 

  182. Kendell RE, Chalmers JC, Plats C. Epidemiology of puerperal psychosis. Br J Psychiatry. 1987;150(5):662–73.

    Article  CAS  PubMed  Google Scholar 

  183. Ahokas A, Aito M, Turiainen S. Association between oestradiol and puerperal psychosis. Acta Psychiatr Scand. 2000;101(2):167–9; discussion 169–70.

    Article  CAS  PubMed  Google Scholar 

  184. Lehman AF, Lieberman JA, Dixon LB, et al. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry. 2004;161(2):1–56.

    PubMed  Google Scholar 

  185. DGPPN. S3 praxisleitlinien in psychiatrie und psychotherapie. Band 1—Behandlungsleitlinie schizophrenie. Dresden: Steinkopff-Verlag; 2006.

    Google Scholar 

  186. Yang FD, Wang XQ, Liu XP, et al. Sex difference in QTc prolongation in chronic institutionalized patients with schizophrenia on long-term treatment with typical and atypical antipsychotics. Psychopharmacology. 2011;216(1):9–16.

    Article  CAS  PubMed  Google Scholar 

  187. Al-Khatib SM, Allen LaPointe NM, Kramer JM, et al. What clinicians should know about the QT interval. JAMA. 2003;289(16):2120–7.

    Article  PubMed  Google Scholar 

  188. Seeman MV. Treating schizophrenia at the time of menopause. Maturitas. 2012;72(2):117–20.

    Article  PubMed  Google Scholar 

  189. Lange B, Mueller JK, Leweke FM, Bumb JM. How gender affects the pharmacotherapeutic approach to treating psychosis—a systematic review. Expert Opin Pharmacother. 2017;18(4):351–62.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Psychiatry, Alava University Hospital-Santiago, Vitoria, Spain

    Ana Isabel Cano-Baena, Laura García-Ayala, Marta Zubía-Martín, Iñaki Zorrilla-Martínez & Ana González-Pinto Arrillaga

  2. University of the Basque Country, UPV/EHU, Leioa, Spain

    Ana González-Pinto Arrillaga

  3. CIBERSAM, Madrid, Spain

    Ana González-Pinto Arrillaga

Authors
  1. Ana Isabel Cano-Baena
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Laura García-Ayala
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Marta Zubía-Martín
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Iñaki Zorrilla-Martínez
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ana González-Pinto Arrillaga
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Iñaki Zorrilla-Martínez .

Editor information

Editors and Affiliations

  1. Cruces University Hospital, University of the Basque Country, Barakaldo, Vizcaya, Spain

    Margarita Sáenz-Herrero

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Cano-Baena, A.I., García-Ayala, L., Zubía-Martín, M., Zorrilla-Martínez, I., González-Pinto Arrillaga, A. (2019). Schizophrenia and Gender. In: Sáenz-Herrero, M. (eds) Psychopathology in Women. Springer, Cham. https://doi.org/10.1007/978-3-030-15179-9_30

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-15179-9_30

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-15178-2

  • Online ISBN: 978-3-030-15179-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation